WO2020159159A3 - 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물 - Google Patents

리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물 Download PDF

Info

Publication number
WO2020159159A3
WO2020159159A3 PCT/KR2020/001162 KR2020001162W WO2020159159A3 WO 2020159159 A3 WO2020159159 A3 WO 2020159159A3 KR 2020001162 W KR2020001162 W KR 2020001162W WO 2020159159 A3 WO2020159159 A3 WO 2020159159A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
lysosomal storage
prevention
storage disorders
treatment
Prior art date
Application number
PCT/KR2020/001162
Other languages
English (en)
French (fr)
Other versions
WO2020159159A2 (ko
Inventor
강경선
홍병희
강인성
유제민
김동훈
Original Assignee
바이오그래핀 주식회사
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오그래핀 주식회사, 서울대학교 산학협력단 filed Critical 바이오그래핀 주식회사
Priority to US17/310,400 priority Critical patent/US20220096540A1/en
Priority to CN202080012042.0A priority patent/CN113498346B/zh
Priority to JP2021544300A priority patent/JP7266801B2/ja
Priority to EP20749590.4A priority patent/EP3919063A4/en
Publication of WO2020159159A2 publication Critical patent/WO2020159159A2/ko
Publication of WO2020159159A3 publication Critical patent/WO2020159159A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C01B32/182—Graphene
    • C01B32/198—Graphene oxide
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
    • C09K11/65—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/01—Particle morphology depicted by an image
    • C01P2004/04—Particle morphology depicted by an image obtained by TEM, STEM, STM or AFM
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/60—Optical properties, e.g. expressed in CIELAB-values

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 리소좀 축적 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 보다 상세하게는 그래핀 양자점을 포함함으로써, 니만픽병을 포함하는 다양한 리소좀 축적 질환에 대하여 우수한 약효를 나타낼 수 있는 약학적 조성물에 관한 것이다.
PCT/KR2020/001162 2019-01-30 2020-01-23 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물 WO2020159159A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/310,400 US20220096540A1 (en) 2019-01-30 2020-01-23 Pharmaceutical composition for prevention or treatment of lysosomal storage disorders
CN202080012042.0A CN113498346B (zh) 2019-01-30 2020-01-23 用于预防或治疗溶酶体贮积症的药物组合物
JP2021544300A JP7266801B2 (ja) 2019-01-30 2020-01-23 リソソーム蓄積症の予防または治療のための薬学的組成物
EP20749590.4A EP3919063A4 (en) 2019-01-30 2020-01-23 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF LYSOSOMIC STORAGE DISEASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0011642 2019-01-30
KR1020190011642A KR102179430B1 (ko) 2019-01-30 2019-01-30 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2020159159A2 WO2020159159A2 (ko) 2020-08-06
WO2020159159A3 true WO2020159159A3 (ko) 2020-10-22

Family

ID=71840203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/001162 WO2020159159A2 (ko) 2019-01-30 2020-01-23 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물

Country Status (6)

Country Link
US (1) US20220096540A1 (ko)
EP (1) EP3919063A4 (ko)
JP (1) JP7266801B2 (ko)
KR (1) KR102179430B1 (ko)
CN (1) CN113498346B (ko)
WO (1) WO2020159159A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102277665B1 (ko) 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
CN114588524B (zh) * 2022-03-21 2023-06-23 温州医科大学 一种用于治疗细菌性角膜炎的基于石墨烯量子点构建的可溶性微针贴片的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130122585A (ko) * 2012-04-30 2013-11-07 서울대학교산학협력단 그래핀 양자점 또는 산화그래핀 양자점을 포함하는 ｍｒｉ 조영제, 및 그 제조방법
CN103845361A (zh) * 2014-03-19 2014-06-11 国家纳米科学中心 石墨烯量子点在制备肿瘤治疗敏化剂中的用途
US20160193249A1 (en) * 2013-09-03 2016-07-07 William Marsh Rice University Treatment of inflammatory diseases by carbon materials
KR101747147B1 (ko) * 2014-04-04 2017-06-14 서울대학교산학협력단 퇴행성 신경 질환의 예방 또는 치료를 위한 그래핀 나노구조체 기반 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022543B2 (en) 2009-01-13 2018-07-17 The Regents Of The University Of Colorado, A Body Corporate Cell stimulation using quantum dots
KR101989169B1 (ko) 2017-07-25 2019-06-14 주식회사 경신 차량용 배터리의 신호 센싱장치
KR102037449B1 (ko) * 2018-02-01 2019-10-28 경희대학교 산학협력단 그래핀 양자점 복합체
WO2020009551A1 (ko) * 2018-07-06 2020-01-09 바이오그래핀 주식회사 신경단백질의 비정상적 섬유화 또는 응집과 관련된 질환 치료제로서의 그래핀 양자점

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130122585A (ko) * 2012-04-30 2013-11-07 서울대학교산학협력단 그래핀 양자점 또는 산화그래핀 양자점을 포함하는 ｍｒｉ 조영제, 및 그 제조방법
US20160193249A1 (en) * 2013-09-03 2016-07-07 William Marsh Rice University Treatment of inflammatory diseases by carbon materials
CN103845361A (zh) * 2014-03-19 2014-06-11 国家纳米科学中心 石墨烯量子点在制备肿瘤治疗敏化剂中的用途
KR101747147B1 (ko) * 2014-04-04 2017-06-14 서울대학교산학협력단 퇴행성 신경 질환의 예방 또는 치료를 위한 그래핀 나노구조체 기반 약학적 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JE MIN YOO, BYUNG HEE HONG, DONGHOON KIM, HANSEOK KO, KYUNGSUN KANG: "SB02.03.09 : Therapeutic Applications of Graphene Quantum Dots for Central Nervous System Disease", 2019 MRS FALL MEETING & EXHIBIT; DECEMBER 1 – 6, 2019; BOSTON, MASSACHUSETTS, USA, 2 December 2019 (2019-12-02), Boston, Massachusetts, USA, pages SB02.03.09, XP009529300 *
KIM, D. ET AL.: "Graphene quantum dots prevent alpha-synucleinopathy in Parkinson's disease", NATURE NANOTECHNOLOGY, vol. 13, no. 9, September 2018 (2018-09-01), pages 812 - 818, XP081105749 *

Also Published As

Publication number Publication date
CN113498346B (zh) 2024-05-03
US20220096540A1 (en) 2022-03-31
CN113498346A (zh) 2021-10-12
KR20200094320A (ko) 2020-08-07
JP2022523317A (ja) 2022-04-22
EP3919063A4 (en) 2022-11-09
WO2020159159A2 (ko) 2020-08-06
EP3919063A2 (en) 2021-12-08
KR102179430B1 (ko) 2020-11-16
JP7266801B2 (ja) 2023-05-01

Similar Documents

Publication Publication Date Title
WO2019227085A8 (en) Designed bacterial compositions and uses thereof
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
WO2008079993A3 (en) Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
EP3965772A4 (en) PHARMACEUTICAL COMPOSITION BASED ON BREXANOLONE, GANAXOLONE OR ZURANOLONE, AND THEIR USE
WO2019209962A8 (en) Compounds and uses thereof
WO2020159159A3 (ko) 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물
EP3894398A4 (en) 3,3-DIFLUORALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2010058926A3 (ko) 생강 추출물 또는 쇼가올을 포함하는 약학 조성물
EP4115895A4 (en) TEA COMPOSITION EFFECTIVE IN PREVENTING OR IMPROVING RESPIRATORY DISEASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
JP2020536085A5 (ko)
WO2019203753A3 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2019209948A8 (en) Compounds and uses thereof
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2021004958A3 (en) Compositions comprising bacterial strains
WO2022063869A3 (en) Compounds for the treatment of viral infections
CA3154083A1 (en) Methods of promoting scfa production by gut microbiota
WO2020250182A3 (ko) 지페노사이드 화합물을 유효성분으로 포함하는 퇴행성 신경질환 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20749590

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021544300

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020749590

Country of ref document: EP

Effective date: 20210830